BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself
BBS-Bioactive Bone Substitutes Plc, Company announcement, 4 September 2023 at 09.45 a.m. EET
BBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself
BBS-Bioactive Bone Substitutes Plc's Board of Directors has decided on 3 September 2023 to issue 500,000 shares without consideration to the company itself, for potential loan conversions as well as for other possible purposes, in accordance with authorisation from the Extraordinary Shareholders' Meeting on 30 March, 2023.
After the directed share issue, the Company holds 601,451 treasury shares, representing approximately 4.1 percent of the total shares and votes of the company.
For more information:
Ilkka Kangasniemi, CEO,
tel. +358 40 708 0307, e-mail: [email protected]
Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, [email protected]
BBS in brief
BBS-Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our developed product, ARTEBONE®, is in the final stages of product development, and we are seeking the CE marking to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ 20 people.
BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.
More information: www.bbs-artebone.fi
